Profile Technologies (PRTK) Narrows Q3 Loss

Go back to Profile Technologies (PRTK) Narrows Q3 Loss

Strong Execution in Q3 Makes Paratek (PRTK) Hard to Resist - Guggenheim

November 12, 2015 11:15 AM EST

Guggenheim affirms Paratek Pharmaceuticals (NASDAQ: PRTK) with a Bu rating and $33 price target after the company... More